Melanoma Drug Shows Promise in Key Trial

Amgen Inc. said its experimental and novel treatment for advanced melanoma met the main goal of a late-stage clinical trial by demonstrating a durable response in significantly more patients than a comparison treatment, the New York Times and Reuters report.